PSSD and PFS: The Overlooked Syndromes No One Warns You About

• 0:00–1:07Framing: PSSD "stumped many in the medical community"; diagnosis by exclusion; no specific treatments; video uses PFS insights to illuminate PSSD.
• 2:08–3:04PFS pharmacology: Finasteride (Propecia/Proscar) selectively inhibits 5AR type 2; dutasteride (Avodart) inhibits types 1+2; sexual side effects can persist after cessation = PFS.
• 3:51–4:54PFS symptom burden: Low libido, ED, decreased arousal persisting 9–16 months post-stop; gynecomastia ~70%; diminished semen; testicular atrophy; genital numbness; brain fog 75%, anxiety 74%, depression/irritability/suicidal ideation 63% (cites Ganz et al. 2015).
• 5:29–7:43Five postulated PFS mechanisms: (1) neuroactive steroid changes — ↓allopregnanolone (notes zuranolone/brexanolone approved for postpartum depression); (2) androgen receptor upregulation + genetic polymorphisms; (3) gene expression changes — 1,446 genes overexpressed / 2,318 underexpressed in penile skin; (4) epigenetic modifications — increased DNA methylation in a gene promoter in CSF; (5) gut-brain axis — finasteride reduces gut microbiome diversity.
• 9:33–10:25PSSD symptom set: Sustained ↓libido; weak/non-pleasurable orgasm; genital anesthesia; persistent ED; "disconnect between sexual thoughts and physical arousal."
• 10:51–14:28Six postulated PSSD mechanisms: (1) serotonergic inhibition of dopamine in nucleus accumbens (→ emotional blunting + sexual dysfunction); (2) neurotoxicity + genetic predisposition (glutamatergic polymorphisms, citalopram/Perlis 2009); (3) endocrine abnormalities — ↓gonadotropins/testosterone, ↑prolactin (dopamine–prolactin inverse relationship); (4) epigenetic DNA methylation with chronic SSRI exposure; (5) neuroactive steroid changes (shared with PFS); (6) gut-brain axis — SSRI-altered microbiome, gut steroid production, inflammation.
• 15:14–18:04Four shared PFS/PSSD mechanisms: (1) sex steroids ↔ dopamine pathways (testosterone → dopamine release in medial preoptic area via nitric oxide synthase); (2) serotonergic inhibition of dopamine (estrogens direct via ER; androgens indirect); (3) noradrenaline/adrenaline balance — finasteride and paroxetine inhibit PNMT (noradrenaline→adrenaline); excess noradrenaline → flaccid state, adrenaline correlates with erection; (4) gut-brain axis dysbiosis in both.
• 18:26–22:24Five treatment avenues (presented as investigational, none established): (1) neuroactive steroid therapy (allopregnanolone/zuranolone/brexanolone; GABA-A positive allosteric modulation; may counteract finasteride-withdrawal gut inflammation); (2) gut microbiome modulation (probiotics); (3) dopamine agonists (bupropion, agomelatine, vortioxetine); (4) epigenetic modulators (DNA methylation inhibitors); (5) hormone replacement therapy. Explicit caveat: "none of these are conclusively established."

Timestamps come from auto-captions and can be off by about five seconds.

This release lists transcript files (CZATt5AoQjw.srt). They are not bundled with the site yet; drop them into corpus/transcripts/ to publish them.